Key points are not available for this paper at this time.
= .048). In a subset of patients (n = 8), cytometry by time of flight comparison of primary cells at pretreatment vs day 8 showed upregulation of pCREB and downregulation of CD11b in nonresponders. In summary, the novel combination of Rux + Ven is safe in adult patients with R/R AML. Our study identified cellular and molecular biomarkers, notably CD56, that predict resistance to Rux + Ven, but further work is needed to understand and validate their effect in AML. This trial was registered at www.clinicaltrials.gov as #NCT03874052.
Borate et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: